Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca’s Crestor proves beneficial for kidney treatment

AstraZeneca’s Crestor proves beneficial for kidney treatment

2nd November 2005

Pharmaceutical giant AstraZeneca has been lifted by research suggesting that its drug Crestor (rosuvastatin calcium) is beneficial in the treatment of kidney disease.

A study published in the American Journal of Cardiology said the drug was effective in reducing inflammation in cases of chronic kidney problems.

Researchers looked at 91 patients and found that those given rosuvastatin showed significantly greater improvements from baseline in low-density lipoprotein cholesterol and hs-CRP.

“In the study, we closely examined patients with established chronic kidney disease-those who would be the most sensitive to therapy that might adversely affect the kidney,” the study’s authors said.

“We saw that there was no deterioration in kidney function in patients who took Crestor, in fact, the measure of kidney function, GFR, tended to increase after treatment with Crestor, although the difference between treated and non-treated patients was not significantly different.”

They added: “This neutral or positive effect on kidney function has been observed consistently in previous Crestor studies, which is important for treating physicians since approximately 19 million US adults have chronic kidney disease.”

The results of the study were largely in line with previous research looking at the performance of Crestor.

Kidney disease is a major a problem in the UK. Figures from Kidney Research UK suggested that as many as one in ten people could be suffering from chronic kidney disease.

track© Adfero Ltd

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.